HPV vaccine - an update

Maharita AR, Izzuna MMG
Record ID 32018002189
English
Authors' objectives: To assess the efficacy or effectiveness, safety, and cost-effectiveness of HPV vaccination at three scenarios: a. Vaccine schedule for young girls (9-15 years old) is reduced to one-dose schedule b. Gap between first dose and second dose is extended up to more than 15 months c. Vaccine schedule for women aged of ≥15 years old is reduce to two-dose schedule
Authors' results and conclusions: Overall efficacy of single dose HPV (either 2vHPV or 4vHPV vaccines) showed significant difference with either 2- or 3-dose. For anogenital wart prevention with 4vHPV vaccine, all doses (1-, 2- or 3-dose) showed significant difference with no dose. GMT level in long interval was higher than short interval. Common long interval reported was about 7- to 12-months and short interval was about 3- to 6-months (no retrievable evidence on ≥15 months interval). Although seropositivity among women 15-25 years old similar in 2-dose and 3-dose schedule, the GMCs level were higher in 3-dose schedule. All HPV dose at any interval had comparable adverse events: pain and redness at injection site. Two doses vaccination was considered ‘very cost-effective’ when one dose protection declines at 10 to 15 years.
Authors' recommendations: Single dose of HPV vaccine and longer interval (7- to 12-months) between 2-dose among girls may be used as an alternative during shortage of HPV vaccine supply. However, for longer interval (≥15 months) and 2-dose of HPV vaccine for adult (women >15 years old) require further assessment.
Authors' methods: Electronic databases were searched through MEDLINE® In-Process and Other Non-Indexed Citations and Ovid MEDLINE® 1946 to 5th February 2021, EBM Reviews – Health Technology Assessment, EBM Reviews – Cochrane Database of Systematic Reviews – 2000 to 5th February 2021, EBM Reviews – Cochrane Central Registered of Controlled Trials February 2021 and EBM Reviews - NHS Economic Evaluation Database ssearches were also run in PubMed, FDA website and INAHTA for any published reports.
Authors' identified further research: Further assessment on local cost-effectiveness study comparing different schedules is warranted.
Details
Project Status: Completed
Year Published: 2021
URL for published report: http://www.moh.gov.my/index.php/database_stores/store_view_page/30/372
Requestor: Ministry of Health, decision-making committee
English language abstract: An English language summary is available
Publication Type: Mini HTA
Country: Malaysia
MeSH Terms
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Infections
  • Uterine Cervical Neoplasms
  • Vaccination
  • Cervical Intraepithelial Neoplasia
  • Young Adult
  • Adolescent
  • Child
  • Female
Keywords
  • HPV
  • vaccine
Contact
Organisation Name: Malaysian Health Technology Assessment
Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229
Contact Name: htamalaysia@moh.gov.my
Contact Email: htamalaysia@moh.gov.my
Copyright: Malaysian Health Technology Assessment Section (MaHTAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.